Inhibition of Wnt signaling, by targeting PDK1 with Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) or Chibby (a β-catenin antagonist) has been shown to reduce glycolytic activity, leading to impaired tumor growth and altered metabolic dependencies (Pate et al., 2014; Zuo et al., 2021; Cai et al., 2018). Here, PDK1 is linked to neoplasm.